ICG (Intermediate Capital Group) is a global alternative asset manager listed on the London Stock Exchange, managing over $126bn in total AUM across private debt, private equity, structured capital, and real assets. Its latest single fund, ICG Strategic Equity V, closed at $11bn in March 2025, focusing on GP-led secondary and structured equity investments.
33% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $960.3M (across 8 rounds with reported amounts).
Portfolio
8
Fund Size
$11B
Top Stage
Growth
Last 12 Mo
0
Team
Andrew Sykes
Senior Independent Director
Jonathon Bond
Independent Non-Executive Director
Matthew Lester
Independent Non-Executive Director
Robin Lawther
Independent Non-Executive Director
Sonia Baxendale
Independent Non-Executive Director
Virginia Holmes
Independent Non-Executive Director
Benoît Durteste
Chief Investment Officer and Chief Executive Officer
Andy Lewis
Global Head of Legal
Adam T. Goodman
Managing Director
Bernard Coady
Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| AAlfa Medicus | Growth | — | Jan 2024 |
 Amolyt Pharma | Series C | $138M | Jan 2023 |
 Amolyt Pharma | Series C | $130M | Jan 2023 |
| EEliem Therapeutics | Series B | $60M | May 2021 |
 Wugen | Series B | $172M | Jan 2021 |
 Parchment | Series D | $23.5M | Oct 2012 |
 Workhuman | Growth | $120M | — |
| CCurium | Unknown | $7B | — |
| EEliem Therapeutics | Series A | $39M | — |
Top Co-Investors
Last updated: 20 October 2026